Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer

被引：0
作者：
Seruga, B. [1 ]
Gan, H. K. [1 ]
Knox, J. J. [1 ]
机构：
[1] Univ Toronto, Princess Margaret Hosp, Dept Med Oncol & Hematol, Div Hematol & Med Oncol, Toronto, ON, Canada
来源：
CURRENT ONCOLOGY | 2009年 / 16卷
关键词：
Sunitinib; sorafenib; temsirolimus; toxicity; side effects; management; RENAL-CELL CARCINOMA; TYROSINE KINASE INHIBITOR; CARDIAC-HYPERTROPHY; INTERFERON-ALPHA; DOUBLE-BLIND; SUNITINIB; HYPOTHYROIDISM; HYPERTENSION; MANAGEMENT; SAFETY;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The toxicities of new, targeted drugs may diminish their effectiveness in advanced kidney cancer if those toxicities are not recognized and properly addressed early in patient treatment. Most of the drug-related toxicities in advanced kidney cancer are manageable with supportive care, obviating a need for long interruptions, dose reductions, or permanent discontinuation of the treatment.
引用
收藏
页码：S54 / S61
页数：8
相关论文
共 50 条
  • [41] Management of immune-mediated toxicities and their implications in the outcomes of advanced kidney cancer
    Roy, Arya Mariam
    George, Saby
    IMMUNOTHERAPY, 2023, 15 (06) : 397 - 400
  • [42] A Retrospective Analysis of Two Different Sequences of Therapy Lines for Advanced Kidney Cancer
    Paglino, Chiara
    Procopio, Giuseppe
    Sabbatini, Roberto
    Bellmunt, Joaquim
    Schmidinger, Manuela
    Bearz, Alessandra
    Bamias, Aristotelis
    Melichar, Bohuslav
    Imarisio, Ilaria
    Tinelli, Carmine
    Porta, Camillo
    ANTICANCER RESEARCH, 2013, 33 (11) : 4999 - 5004
  • [43] Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer
    Takami, Hiroshi E.
    ENDOCRINE JOURNAL, 2011, 58 (03) : 151 - 153
  • [44] Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017
    Reaume, M. Neil
    Basappa, Naveen S.
    Wood, Lori
    Kapoor, Anil
    Bjarnason, Georg A.
    Blais, Normand
    Breau, Rodney H.
    Canil, Christina
    Cheung, Patrick
    Conter, Henry J.
    Hotte, Sebastien J.
    Jeldres, Claudio
    Jewett, Michael A. S.
    Karakiewicz, Pierre I.
    Kollmannsberger, Christian
    Patenaude, Francois
    So, Alan
    Soulieres, Denis
    Venner, Peter
    Violette, Phillippe
    Zalewski, Pawel
    Chappell, Heather
    North, Scott A.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2017, 11 (10): : 310 - 320
  • [45] Managing dermatologic changes of targeted cancer therapy
    Zarrabi, Kevin
    Gemmill, Julie Anne L.
    Safaee, Maryam
    Baer, Lea
    JOURNAL OF FAMILY PRACTICE, 2019, 68 (06) : 334 - 340
  • [46] Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions
    Curry, Jonathan L.
    Torres-Cabala, Carlos A.
    Kim, Kevin B.
    Tetzlaff, Michael T.
    Duvic, Madeleine
    Tsai, Kenneth Y.
    Hong, David S.
    Prieto, Victor G.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2014, 53 (03) : 376 - 384
  • [47] Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer
    Rosellini, Matteo
    Marchetti, Andrea
    Tassinari, Elisa
    Nuvola, Giacomo
    Rizzo, Alessandro
    Santoni, Matteo
    Mollica, Veronica
    Massari, Francesco
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2022, 7 (01): : 131 - 149
  • [48] Effects of Antiangiogenetic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer
    Dalbeni, Andrea
    Ciccarese, Chiara
    Bevilacqua, Michele
    Benati, Marco
    Caimmi, Cristian
    Cerrito, Luca
    Fama, Federico
    Iacovelli, Roberto
    Mantovani, Anna
    Meneguzzi, Francesco Massari Alessandra
    Minuz, Pietro
    Montagnana, Martina
    Orsolini, Giovanni
    Rossini, Maurizio
    Tortora, Gianpaolo
    Viapiana, Ombretta
    Fava, Cristiano
    CANCERS, 2019, 11 (01)
  • [49] Sorafenib is the first targeted agent to treat metastatic kidney cancer
    Matveev, V. B.
    Chernyaev, V. A.
    ONKOUROLOGIYA, 2015, 11 (01): : 73 - 78
  • [50] New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management
    Frank Kroschinsky
    Friedrich Stölzel
    Simone von Bonin
    Gernot Beutel
    Matthias Kochanek
    Michael Kiehl
    Peter Schellongowski
    Critical Care, 21
12345